Market News

Breaking headlines and analysis across every asset class.

Earnings
AD HOC NEWS • Oct 2, 2026
Jabil reports 24.00 percent revenue growth outlook and Jabil stock gains 1.45 percent

Jabil Inc. reported a significant revenue increase for fiscal year 2026, reaching USD 35.95 billion, and provided an ambitious outlook for fiscal 2027 with expected revenue of USD 44.50 billion, a 24.00 percent increase. The company's stock responded positively, gaining 1.45 percent, driven by strong fourth-quarter earnings and a projected surge in AI-related revenue. Analysts maintain a positive stance on Jabil, with JPMorgan raising its price target, indicating confidence in the company's grow

Earnings
Investing.com • Oct 2, 2026
Raymond James reiterates Comcast stock rating ahead of earnings By Investing.com

Raymond James has reiterated a Market Perform rating on Comcast (NASDAQ: CMCSA) ahead of its Q3 2026 earnings report, citing a multiyear competitive shift in the cable sector that could limit upside potential and lead to a lower valuation for the stock. The firm is updating its financial model and revising revenue, EBITDA, non-GAAP EPS, and free cash flow per share estimates for 2026 and 2027, following Comcast's spin-out of Sky Germany. Despite recent strong Q2 2026 results, the stock is tradin

Earnings
Moomoo • Oct 2, 2026
BCE Inc. Is Maintained at Outperform by National Bank

National Bank has reiterated its "Outperform" rating for BCE Inc. The article also mentions Unity Software's fourth-quarter financial results, reporting a 35% year-over-year revenue increase to $609 million, exceeding estimates, despite a quarterly loss of 66 cents per share.

Earnings
Investing.com • Oct 1, 2026
Scotiabank reiterates CMS Energy stock rating on growth outlook

Scotiabank has reiterated its Sector Outperform rating and $78.00 price target for CMS Energy (NYSE:CMS), citing the company's growth outlook and an attractive entry point for long-term returns. Despite recent underperformance and trading near its 52-week low, the firm maintains a bullish stance, highlighting CMS Energy's consistent dividend increases and strategic shift towards utility growth. The company aims for the higher end of its 6-8% earnings per share compound annual growth rate and has

Earnings
Investing.com • Oct 1, 2026
Jefferies reiterates Teledyne stock rating on positive revision cycle

Jefferies has reiterated a Buy rating on Teledyne Technologies Inc. (NYSE:TDY) with a price target of $830.00, anticipating the company will surpass its third-quarter revenue and earnings expectations. The firm believes Teledyne is in the early stages of a positive estimate revision cycle, backed by strong financial health indicated by a Piotroski Score of 9. This positive outlook follows Teledyne's impressive second-quarter results, which led to increased full-year guidance and analyst price ta

Earnings
Investing.com • Oct 1, 2026
Wells Fargo raises FactSet stock price target on AI momentum

Wells Fargo increased its price target for FactSet Research Systems (NYSE:FDS) to $250 from $210, citing strong fourth-quarter performance driven by AI momentum, despite maintaining an Underweight rating on the stock. Although FactSet beat Street estimates for EPS and organic annual subscription value growth in Q4, its fiscal 2027 guidance for these metrics fell slightly below expectations. The company demonstrated significant growth in AI and data solutions, with over 10% of its Q4 annual subsc

Earnings
AD HOC NEWS • Oct 1, 2026
LeMaitre Vascular stock hits 52-week low as analysts hold

LeMaitre Vascular (LMAT) reached a new 52-week low of USD 78.22, despite analysts holding an average price target of USD 110.60. The company's second-quarter revenue of USD 70.38 million missed consensus estimates, as did diluted earnings per share, leading to a focus on execution against expectations. Despite the miss, revenue grew by 9.60% year-over-year, and the company provided positive 2026 full-year sales and earnings per share guidance.

Earnings
AD HOC NEWS • Oct 1, 2026
Kymera Therapeutics stock reports 465.2 percent revenue growth

Kymera Therapeutics reported a significant 465.2% year-over-year revenue growth in Q2 2026, reaching USD 65.0 million, primarily driven by collaboration income. The company also beat analyst estimates for adjusted loss per share. Stifel Nicolaus raised its price target for Kymera to USD 152.00, maintaining a Buy rating, highlighting the company's platform in targeted protein degradation and oral medicines for inflammatory diseases.

Earnings
AD HOC NEWS • Oct 1, 2026
JPMorgan upgrades Welltower stock to Overweight at USD 260

JPMorgan has upgraded Welltower (WELL) stock from Neutral to Overweight, maintaining a price target of USD 260. The upgrade reflects the analyst's view of Welltower's visible, multi-year growth and strong same-store net operating income performance. Welltower reported significant revenue and net income growth in Q2 2026 and is set to release Q3 2026 results on October 26, 2026.

Get Headlines in Your Inbox

One email a day with the market-moving stories you actually need to read.